Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide cardiovascular outcomes trial in adults with type 2 diabetes
2012-002839-28Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Oct 2012
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Semaglutide plus standard of care with Placebo plus standard of care (2 arms). Started Oct 2012; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2012-002839-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002839-28.